NIMS’ Exer-Rest® Technology Presented at American Heart Association Symposium

Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB: NIMU) announced that Dr. Jose A. Adams of Mount Sinai Medical Center - Miami Beach, was invited to present a paper in the Symposium, “From Endothelial Biology to Therapy” at the November 2009 American Heart Association meeting in Orlando, Florida.

Dr. Adams spoke on “Endothelium During Cardiac Arrest,” focusing on ischemia/reperfusion (I/R) injury, in which tissues are damaged due to diminished blood supply with additional damage after circulation is restored. He indicated that cardiac arrest followed by CPR is an example of global I/R injury, while myocardial infarction and stroke are localized I/R injuries. Adverse outcomes from global and localized I/R injuries largely relate to damaged vascular endothelium, the lining layer of blood vessels and heart. Dr. Adams concluded that such damage can be ameliorated by Whole Body Periodic Acceleration (WBPA) therapy, in which the entire body is moved repetitively in a head-foot motion while lying in a supine position.

“We are pleased that Dr. Adams’ research supports the potential of NIMS’ Exer-Rest therapeutic platform, which utilizes WBPA technology, to improve clinical outcomes following cardiac arrest, myocardial infarction and stroke,” said Dr. Marvin Sackner, CEO of NIMS.

FDA has cleared Exer-Rest to temporarily increase local circulation, provide temporary relief of minor aches and pains, reduce morning stiffness and provide local muscle relaxation. The Exer-Rest has not been cleared by FDA for treating I/R injuries. Dr. Adams serves as a member of the NIMS Scientific Advisory Board.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks and uncertainties associated with potential benefits of WBPA therapy and the use of Exer-Rest platforms, dependence on future sales of the Exer-Rest, obtaining regulatory approvals, establishing marketing, sales and distribution activities, the uncertainty of future financial results, additional financing requirements, development of new products, technological changes, and other uncertainties. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.